Sigilon Therapeutics, Inc.

The momentum for this stock is not very good. Sigilon Therapeutics, Inc. is not a good value stock. Sigilon Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Sigilon Therapeutics, Inc..
Log in to see more information.
SGTX Fundamental Data by TradingView

News

Lilly & Co Eli Acquires 1,718,493 Shares of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Stock
Lilly & Co Eli Acquires 1,718,493 Shares of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Stock

Ticker Report Sigilon Therapeutics, Inc. (NASDAQ:SGTX Get Free Report) major shareholder Lilly Co Eli acquired 1,718,493 shares of the firms stock in a transaction that occurred on Friday...\n more…

Lilly & Co Eli Purchases 1,718,493 Shares of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Stock
Lilly & Co Eli Purchases 1,718,493 Shares of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Stock

Zolmax Sigilon Therapeutics, Inc. (NASDAQ:SGTX Get Free Report) major shareholder Lilly & Co Eli purchased 1,718,493 shares of the companys stock in a transaction dated Friday, August 11th. The stock was purchased at an average cost of $14.92 per share, with a total value of $25,639,915.56. Following the ...\n more…

Eli Lilly completes acquisition of Sigilon Therapeutics
Eli Lilly completes acquisition of Sigilon Therapeutics

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Lilly Completes Acquisition of Sigilon Therapeutics
Lilly Completes Acquisition of Sigilon Therapeutics

PR Newswire Lilly Completes Acquisition of Sigilon Therapeutics Lilly Completes Acquisition of Sigilon Therapeutics PR Newswire INDIANAPOLIS, Aug. 14, 2023 INDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly...\n more…

SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, In
SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, In

Business Wire Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Sigilon Therapeutics, Inc. (NasdaqGS: SGTX) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders...\n more…

SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, In
SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, In

Business Wire Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Sigilon Therapeutics, Inc. (NasdaqGS: SGTX) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders...\n more…